TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06788548

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: combined endoscopic-laparoscopic sentinel lymph node navigation surgery
Description: 1. Determination of tumor location and sentinel lymph node: endoscopic staining (2mg indocyanine green, four-quadrant submucosal injection) was used to determine the location of the lesion during laparoscopic surgery combined with endoscopic localization to ensure effective and safe resection margins. The staining technique was used to identify the sentinel lymph nodes basin, and en bloc resection of the lymph node basin biopsy was performed.~2. Standard of lymph node basin dissection: All sentinel nodes are located within the lymphatic basin, which is considered the primary lymphatic drainage area for each patient. Follow the SENORITA trail criteria\[9\], lymphatic basin is delineated by the distribution of dye within the lymphatic channels, as seen in dye mapping. The proximal extent of the lymphatic basin is demarcated by the fatty tissue adjacent to the stomach wall, while the distal boundary is marked by the most distant stained node from the stomach.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic D2 radical gastrectomy
Description: Preparation: The patient is positioned supine with general anesthesia. An orogastric tube and Foley catheter are inserted. Antibiotics are administered, and sequential stockings are applied. Port Placement: Pneumoperitoneum is created via a Veress needle at the umbilicus. Working ports are placed in the upper quadrants, with a fifth port for liver retraction. Abdominal Exploration: The abdomen is inspected for metastases, and peritoneal cytology is performed. Dissection and Lymph Node Removal: The lesser omentum is divided near the liver, reaching the cardia and diaphragm. The gastrocolic ligament is divided along the transverse colon. Lymph node dissection begins along the splenic artery, then proceeds to the left gastric artery and celiac nodes. The left gastric vessels are controlled with endoclips.After lymph node dissection, distal subtotal gastrectomy is performed. Digestive tract reconstruction is typically done through a mini-laparotomy.
Study: NCT05898607

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: continuous Erector spinae plane block
Description: continuous U/S-Guided ESPB of 5 ml/hr of 0.125% bupivacaine started through the catheter before the surgical procedure
Study: NCT06458335

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Therapy for Perceived Social Isolation
Description: 6 sessions focused on addressing thoughts, emotions, and behaviors that maintain feeling alone as a way to reduce loneliness and substance use

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health Education
Description: Health education provides information on the importance and benefits of and guidelines for living a health lifestyle

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health Education
Description: Health education provides information on the importance and benefits of and guidelines for living a health lifestyle
Study: NCT06789042

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.9%NaCl
Description: 20ml 0.2% Ropivacaine + 2.0ml 0.9% NaCl

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone 4mg
Description: 20ml 0.2% Ropivacaine + 4mg Dexamethasone
Study: NCT06785337

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled nitroglycerin
Description: Inhaled nitroglycerin
Study: NCT06789185

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.1mg/kg esketamine
Description: Intravenous injection 0.1mg/kg esketamine about 5min before the end of the surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.2mg/kg esketamine
Description: Intravenous injection 0.2mg/kg esketamine about 5min before the end of the surgery

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.1ml/kg normal saline
Description: Intravenous injection 0.1ml/kg normal saline about 5min before the end of the surgery
Study: NCT06788197

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-A1811+fulvestrant
Description: Cohort A will receive treatment with SHR-A1811 and fulvestrant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-A1811 +Fulvestrant +HS-10352
Description: Cohort B will receive treatment with SHR-A1811+Fulvestrant+HS-10352
Study: NCT05083416

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prolonged Nightly Fasting
Description: Limiting daily period of food intake to 10 hours and nightly fasting period to 14 hours.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Regular Eating pattern
Description: Food intake not limited to a specific time during day/night.
Study: NCT06788977

Intervention type: DEVICE
Intervention: external Trigeminal Nerve Stimulation
Description: External trigeminal nerve stimulation (e-TNS) is a non-invasive, nondrug option for the acute and preventative treatment of migraine. The device is marketed under the trade name CEFALY and has received clearance from the US Food and Drug Administration (FDA) for the acute and preventative treatment of migraine.~The CEFALY device provides transcutaneous stimulation of the supraorbital and supratrochlear branches of the ophthalmic division of the Trigeminal nerve. Patients apply a self-adhesive electrode pad to their forehead, then place the CEFALY generator over the electrodes, resulting in a magnetic connection. The user then selects a treatment program for acute or preventative therapy, which lasts for 60 or 20 minutes.
Study: NCT06789133

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PNF exercises and Body weight supported treadmill gait training
Description: PNF Exercises:~.Proprioceptive neuromuscular facilitation exercises include D1 Flexion and D1 Extension of lower limb ,D2 flexion D2 extension of lower limb .rhythmic initiation ,hold relax ,pelvic pattern and contract relax technique . subjects will perform each exercise for 30sec with resting interval of 30 to 60 seconds Will be provided after completion of each exercise. 3 sessions will be held per week, For 8 weeks~Gait training:~Body weight supported treadmill gait training for 20 minutes 3 sessions per week.~In total all PNF exercises with gait training will be held for 40-45 minutes.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Body weight supported treadmill gait training and Routine physical therapy
Description: Body Weight Supported Treadmill Training (BWSTT):~This will include body weight supported treadmill gait training. 10 % BWSTT or 20% BWSTT. The session will of 20 minutes .3 sessions will be Held per week.~Routine physical therapy:~Stretching and strengthening of lower extremities In total all BWSTT along with routine physical therapy protocol will be held for 40-45minutes .3 sessions will be held per week.
Study: NCT04380454

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Functional electrical stimulation (FES)
Description: Functional electrical stimulation (FES) is a targeted intervention that provides motor level stimulation-induced cues to improve ankle propulsion. An electrical stimulator will be used to deliver stimulation during walking (Grass S8800 stimulator with SIU8TB stimulus isolation unit; UDel stimulator). A customized, real-time system will be used to control the stimulator and deliver stimulation during appropriate phases of the gait cycle. Stimulation will be delivered to the ankle dorsiflexors when the subject's foot is in the air (swing phase). Stimulation will be delivered to the ankle plantarflexors during the terminal stance phase of gait. 30-Hz variable frequency stimulation trains 170 will be delivered during gait. The intervention comprises 3 training sessions per week for a total of 12 training sessions. FES intensity is determined at the start of every training session as motor-level stimulation that elicits appropriate functional movements.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fast treadmill walking
Description: Fast treadmill walking (Fast) is a non-targeted intervention where no specific instructions are provided to target practice to the paretic leg or specific ankle deficits. The intervention comprises 3 training sessions per week for a total of 12 training sessions. Each training session includes six 6-minute walking bouts with 5-minute breaks between bouts.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fast treadmill walking
Description: Fast treadmill walking (Fast) is a non-targeted intervention where no specific instructions are provided to target practice to the paretic leg or specific ankle deficits. The intervention comprises 3 training sessions per week for a total of 12 training sessions. Each training session includes six 6-minute walking bouts with 5-minute breaks between bouts.
Study: NCT05806697

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Electroencephalogram (EEG)
Description: The EEG will be uniquely performed during for the whole study if a given subject converts to symptomatic AD or in the occurrence of significant cognitive decline.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Oculomotor tests
Description: All participants in the INSIGHT-2 study are invited to perform the oculomotor test, excepting subjects reporting oculomotor disorders.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: MRI
Description: All INSIGHT-2 participants will undergo a baseline MRI (structural and resting state fMRI) a follow-up MRI at M12, M36 and M60.

Intervention type: RADIATION
Group type: OTHER
Intervention: 18-F amyloid PET Scan
Description: The primary endpoint is conversion to the symptomatic stage in subjects at risk, identified by positive amyloid staining (A+) on florbetapir PET imaging. Participants will receive an injection of 18F-Florbetapir prior to undergoing amyloid PET scanning. Florbetapir (18F) is an experimental imaging compound labeled with \[18F\] fluorine that decays by positron (β+) emission and has a half-life of 109.77 min. This procedure will be done at baseline.

Intervention type: RADIATION
Group type: OTHER
Intervention: 18F-fluorodeoxyglucose (FDG) PET Scan
Description: Participants will receive an injection of Fludeoxyglucose 18F prior to undergoing FDG-PET. The \[18F\]FDG is the most well-known radiopharmaceutical positron emitter, in both clinical and preclinical fields.

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Blood sampling
Description: A total of 80 ml of whole blood will be collected for each participant in the INSIGHT-2 study for routine laboratory assessment and biobank sampling.

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Lumbar puncture
Description: A lumbar puncture for cerebrospinal fluid (CSF) collection is proposed to all participants.
Study: NCT05252962

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Collagen Peptides
Description: Collagen peptides will be orally administered and pharmacokinetic parameters will be assessed up to 6 hours after study product intake.
Study: NCT05918328

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albumin paclitaxel+trastuzumab+pyrrolitinib
Description: Albumin paclitaxel 260mg/m 2+trastuzumab (initial loading dose 8 mg/kg, sequential maintenance dose 6 mg/kg)+pyrrolitinib (320mg, QD), one cycle every 21 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Docetaxel+Carboplatin+trastuzumab+Parstuzumab
Description: Docetaxel 75 mg/m2+carboplatin (AUC=6)+trastuzumab (initial loading dose 8 mg/kg, sequential maintenance dose 6 mg/kg)+patuzumab (initial loading dose 840mg, sequential maintenance dose 420 mg), one cycle every 21 days
Study: NCT05559736

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Artemis Proximal Femoral Nail (PFN) implant
Description: Artemis Proximal Femoral Nail (PFN) implant
Study: NCT04389372

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness
Description: Mindfulness by smartphone combined to video calls for clinical evaluation in patients with chronic migraine and medication overuse after withdrawal program
Study: NCT06358469

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgery
Description: Re-excision of vulvar cancer margin

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Active Surveillance
Description: The investigator will follow the patient to watch for side effects and keep track of patient's health

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Active Surveillance
Description: The investigator will follow the patient to watch for side effects and keep track of patient's health
Study: NCT04988074

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cemiplimab
Description: Cemiplimab for 9 weeks +/- Carboplatin + Paclitaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cemiplimab
Description: Cemiplimab for 9 weeks +/- Carboplatin + Paclitaxel
Study: NCT04718025

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ticagrelor 90mg
Description: Up to day 30 after ACS, all enrolled patients will receive standard-dose ticagrelor 2x90mg as a part of dual antiplatelet therapy. Participants in SDTA arm will continue treatment with ticagrelor 2x90mg until 12 months post-ACS, while patients in LDTA and LDTP will be switched to low-dose ticagrelor 2x60 mg starting on day 31.
Study: NCT05639595

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Web interface for health center staff and mobile application on smart phones for village health volunteers
Description: The designated health center staff will receive a web interface that will allow them to offer job aid for supervision, including real-time information about VHSGs' performance in the form of process indicators and coverage of MCH services. The tool will also support health center staff in their daily tasks, such as high-risk patient tracking, low-supply-inventory alerts, supply chain management, electronic health records, vital events tracking, and automatic calculation of performance-based incentives and motivation for VHSGs. The mobile application will be offered to two female VHSGs from each of the 200 villages connected to their respective health centers in the intervention arm. The mobile application will provide job aid to VHSGs for scheduling home visit tasks, including ANC, home-based newborn care, reporting outcomes of pregnancies, and follow-up visits of complicated cases.
Study: NCT04718025

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor 60mg
Description: Starting from day 31, LDTA and LDTP patients will receive low-dose ticagrelor 2x60mg until 12 months post-ACS.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor 60mg
Description: Starting from day 31, LDTA and LDTP patients will receive low-dose ticagrelor 2x60mg until 12 months post-ACS.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: Up to day 90 after ACS, all enrolled patients will receive aspirin 1x100mg as a part of dual antiplatelet therapy. Starting from day 91, LDTP patients will discontinue aspirin and proceed with low-dose ticagrelor monotherapy until 12 months post-ACS, while patients in LDTA and SDTA will continue aspirin 1x100 mg until 12 months post-ACS.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: Up to day 90 after ACS, all enrolled patients will receive aspirin 1x100mg as a part of dual antiplatelet therapy. Starting from day 91, LDTP patients will discontinue aspirin and proceed with low-dose ticagrelor monotherapy until 12 months post-ACS, while patients in LDTA and SDTA will continue aspirin 1x100 mg until 12 months post-ACS.
Study: NCT06263959

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GST-HG131
Description: GST-HG131 will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GST-HG131
Description: GST-HG131 will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GST-HG131
Description: GST-HG131 will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to match GST-HG131
Description: Placebo to match GST-HG131 will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to match GST-HG131
Description: Placebo to match GST-HG131 will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to match GST-HG131
Description: Placebo to match GST-HG131 will be administered.
Study: NCT06022419

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lucerne Cast
Description: Patients receiving reduction of fractured finger and subsequent customization of a lucerne cast. Duration of cast treatment is determined with 4 weeks.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Forearm Cast and Finger Splint
Description: Patients receiving reduction of fractured finger and subsequent customization of a forearm cast with a finger splint. Duration of cast treatment is determined with 4 weeks.
Study: NCT06169605

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: removal of primary tumor, neck dissection
Description: removal of the primary tumor with safety margins and removal of the neck lymph node levels I, II, III and IV. histological assessment of tumor thickness and whether it is associated with positive nodes in level IV or not.
Study: NCT05645003

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High-frequency real-time rTMS protocol
Description: It was planned to apply a total of 1200 beats to the dorsolateral prefrontal cortex daily for 15 sessions. Along with the daily rTMS session, patients will continue to use the drugs in the medical treatment (pregabalin, gabapentin, carbamazepine) at the same effective dose. No dose changes will be made during rTMS sessions.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham rTMS Protocol
Description: It was planned to apply a to the dorsolateral prefrontal cortex daily for 15 sessions. Along with the daily rTMS session, patients will continue to use the drugs in the medical treatment (pregabalin, gabapentin, carbamazepine) at the same effective dose. No dose changes will be made during rTMS sessions.
Study: NCT06630325

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Given PO
Study: NCT05539339

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Individualized intervention based on genomic alterations
Description: Specialized tumor board recommended agents that target the specific recurrence-driving genomic alterations that are determined by serial TISF ctDNA analysis.
Study: NCT03258658

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous Engineered Urethral Construct
Description: urethral construct
Study: NCT04809103

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cis-diamminedichloroplatinum
Description: Cisplatin delivered bronchoscopically at the time of diagnosis of NSCLC
Study: NCT05641142

Intervention type: OTHER
Group type: OTHER
Intervention: monitoring the use of anticoagulant and/or antiplatelet therapy in patients with osler rendering disease
Description: Monitoring:~* hemoglobin and ferritin levels~* transfusion or intravenous iron~* hospitalization for bleeding or thrombose~* digestive bleeding and/or another haemorrhagic accident~* severity of epistaxis~* quality of life
Study: NCT04889976

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Double Active: Active portable transcranial stimulation (ptES) and active internet-based behavioral therapy (iBT)
Description: ptES is delivered by the Flow device (Flow Neuroscience, Malmö, Sweden), consisting of a one-size-fits-all, transcranial direct current stimulation (tDCS) headset with circular electrodes (area = 22.9cm2). The anode is positioned over the left prefrontal cortex, and the cathode over the right prefrontal cortex. Current strength is set at 2mA (current density = 0.087mA/cm2) for 30 minutes, daily for 5 continuous days (with a 2-day pause) for the first 3 weeks, with twice-weekly sessions for the following 3 weeks (total of 21 sessions in 6 weeks). Active iBT consists of a smartphone app with an electronic therapist-avatar. The iBT sessions are delivered concomitantly to the tDCS sessions (the tDCS device connects via bluetooth to the participant's smartphone app).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ptES-only: Active portable transcranial stimulation (ptES) and sham internet-based behavioral therapy (iBT)
Description: ptES is delivered by the Flow device (Flow Neuroscience, Malmö, Sweden), consisting of a one-size-fits-all, transcranial direct current stimulation (tDCS) headset with circular electrodes (area = 22.9cm2). The anode is positioned over the left prefrontal cortex, and the cathode over the right prefrontal cortex. Current strength is set at 2mA (current density = 0.087mA/cm2) for 30 minutes, daily for 5 continuous days (with a 2-day pause) for the first 3 weeks, with twice-weekly sessions for the following 3 weeks (total of 21 sessions in 6 weeks). The sham iBT sessions are delivered concomitantly to the active ptES sessions (the ptES device connects via bluetooth to the participant's smartphone app).

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Double-sham: Sham portable transcranial stimulation (ptES) and sham internet-based behavioral therapy (iBT)
Description: Sham ptES for this trial is delivered by the Flow device (Flow Neuroscience, Malmö, Sweden), consisting of a one-size-fits-all transcranial direct current stimulation (tDCS) headset, with circular electrodes (area = 22.9cm2). The anode is positioned over the left prefrontal cortex, and the cathode over the right prefrontal cortex. The sham protocol consists of a fade-in and fade-out phases of 1mA for 45 seconds, followed by a silent period in between for the remaining 28 1/2 minutes. The sham iBT sessions are delivered concomitantly to the sham ptES sessions (the ptES device connects via bluetooth to the participant's smartphone app).
Study: NCT04341376

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced First Connections
Description: Enhanced First Connections is a short-term home visiting program that includes prenatal identification and engagement of women with an adversity or trauma history, and infant and early childhood mental health consultation.
Study: NCT05560308

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab Emtansine for Injection
Description: 3.6 mg/kg body weight (IV), administered on day 1, 21 days as a treatment cycle;

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyrotinib Maleate Tablets
Description: The initial dose is 320 mg (PO), administered orally within 30 minutes after meals, at the same time every day, 21 days as a treatment cycle;
Study: NCT06202092

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Phonophoresis
Description: Ultrasound using honey as a media over the knee joint

Intervention type: DEVICE
Group type: OTHER
Intervention: Ultrasound
Description: ultrasound using gel as a media over the knee joint

Intervention type: PROCEDURE
Group type: OTHER
Intervention: conventional physiotherapy
Description: TENS, Strengthening, and stretching exercises

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional physiotherapy
Description: TENS, Strengthening, and stretching exercises
Study: NCT06453642

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GPX® Embolic Device
Description: Treatment includes distal embolization in the peripheral vasculature of vascular tumors, renal embolization, and portal vein branches